Article ; Online: The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
2015 Volume 193, Issue 5, Page(s) 1494–1499
Abstract: Purpose: It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. We evaluated the effect of concomitant clinical carcinoma in situ on cancer specific outcomes after neoadjuvant ... ...
| Abstract | Purpose: It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. We evaluated the effect of concomitant clinical carcinoma in situ on cancer specific outcomes after neoadjuvant chemotherapy for muscle invasive bladder cancer. Materials and methods: We performed an institutional review board approved, multi-institutional, retrospective review of the records of patients treated with neoadjuvant chemotherapy followed by radical cystectomy for muscle invasive bladder cancer from 2008 to 2012. Pretreatment clinical variables were collected and patients were stratified by the presence of clinical carcinoma in situ on precystectomy transurethral bladder tumor resection specimens. Pathological outcomes, including the complete response rate (pT0N0Mx) after neoadjuvant chemotherapy, were compared between the 2 groups. Recurrence-free, cancer specific and overall survival was analyzed. Results: Of 189 patients who met study criteria 56 (29.6%) had concomitant carcinoma in situ. The condition was associated with a significant decrease in the pathological complete response rate (10.7% vs 26.3%, p = 0.02). This difference was significant on univariate and multivariable analysis (OR 0.34, 95% CI 0.13-0.85, p = 0.02 and OR 0.31, 95% CI 0.12-0.81, p = 0.02, respectively). Despite the decreased complete response rate clinical carcinoma in situ was not associated with a difference in recurrence-free, cancer specific or overall survival. Additionally, when down-staging to pathological carcinoma in situ only disease was considered a complete response, there was no significant change in recurrence-free, cancer specific or overall survival. Conclusions: Concomitant carcinoma in situ is associated with a decrease in the complete response rate but this does not appear to impact the survival outcome. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Carcinoma in Situ/drug therapy ; Carcinoma in Situ/pathology ; Carcinoma in Situ/surgery ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/surgery ; Chemotherapy, Adjuvant ; Cystectomy ; Humans ; Neoadjuvant Therapy ; Neoplasms, Multiple Primary/drug therapy ; Neoplasms, Multiple Primary/pathology ; Neoplasms, Multiple Primary/surgery ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2015-05 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Evaluation Studies ; Journal Article ; Multicenter Study ; Validation Studies | ||||||||||
| ZDB-ID | 3176-8 | ||||||||||
| ISSN | 1527-3792 ; 0022-5347 | ||||||||||
| ISSN (online) | 1527-3792 | ||||||||||
| ISSN | 0022-5347 | ||||||||||
| DOI | 10.1016/j.juro.2014.11.003 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ui VI Zs.91: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 331: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.